Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise

Timothy E.G. Krueger, Daniel L.J. Thorek, Samuel R Denmeade, John Tod Isaacs, William Brennen

Research output: Contribution to journalReview article

Abstract

The development of mesenchymal stem cells (MSCs) as cell-based drug delivery vectors for numerous clinical indications, including cancer, has significant promise. However, a considerable challenge for effective translation of these approaches is the limited tumor tropism and broad biodistribution observed using conventional MSCs, which raises concerns for toxicity to nontarget peripheral tissues (i.e., the bad). Consequently, there are a variety of synthetic engineering platforms in active development to improve tumor-selective targeting via increased homing efficiency and/or specificity of drug activation, some of which are already being evaluated clinically (i.e., the good). Unfortunately, the lack of robust quantification and widespread adoption of standardized methodologies with high sensitivity and resolution has made accurate comparisons across studies difficult, which has significantly impeded progress (i.e., the ugly). Herein, we provide a concise review of active and passive MSC homing mechanisms and biodistribution postinfusion; in addition to in vivo cell tracking methodologies and strategies to enhance tumor targeting with a focus on MSC-based drug delivery strategies for cancer therapy. Stem Cells Translational Medicine 2018;1–13.

Original languageEnglish (US)
Pages (from-to)651-663
Number of pages13
JournalStem cells translational medicine
Volume7
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

    Fingerprint

Keywords

  • Cell size
  • Cell-based therapy
  • Drug delivery
  • Homing
  • In vivo cell tracking
  • Mesenchymal stem cell

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this